GlassScriptPhysician profile
Timothy C Gabriel
NPI 1992710875
$11,611.35
in general payments reported to CMS, 2019-2025
44 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $1,605 · 2021: $1,891 · 2022: $2,020 · 2023: $1,465 · 2024: $1,652 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,721.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,633.53 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,192.70 | 2019-2025 | Xifaxan |
| Amgen INC. | $1,028.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $630.75 | 2019-2024 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $599.98 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $414.35 | 2019-2024 | Hetlioz, Fanapt |
| Glaxosmithkline, LLC. | $312.88 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $310.73 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $298.05 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $291.51 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $288.05 | 2019-2024 | |
| Grifols USA, LLC | $280.35 | 2019-2023 | Prolastin-C Liquid |
| Radius Health, INC. | $278.98 | 2019-2025 | |
| Astellas Pharma US INC | $258.62 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.